HOOKIPA PHARMA INC. Forms 3, 4 and 5: Stock Options
Statements of beneficial ownership filed with the SEC by officers, directors and 10% owners: 23 rows in 2022. Transaction codes are the SEC's. Shares and prices are split-adjusted; the as-filed figure is underneath.
- 2022-06-30: Reporting owner van de Winkel Jan; Form 4; Security Stock Option (Right to Buy); Transaction A Grant, award or other acquisition pursuant to Rule 16b-3(d).
- 2022-06-30: Reporting owner Reilly Timothy P.; Form 4; Security Stock Option (Right to Buy); Transaction A Grant, award or other acquisition pursuant to Rule 16b-3(d).
- 2022-06-30: Reporting owner Orlinger Klaus; Form 4; Security Stock Option (Right to Buy); Transaction A Grant, award or other acquisition pursuant to Rule 16b-3(d).
- 2022-06-30: Reporting owner O'Neill Julie; Form 4; Security Stock Option (Right to Buy); Transaction A Grant, award or other acquisition pursuant to Rule 16b-3(d).
| Transaction date | Reporting owner | Form | Security | Transaction | Shares | Price | Price that day | Filing |
|---|---|---|---|---|---|---|---|---|
| 2022-06-30 | van de Winkel Jan Director | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +40,000 40,000 owned after | $1.63 exercise price | 2022-07-01 | |
| 2022-06-30 | Reilly Timothy P. Director | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +40,000 40,000 owned after | $1.63 exercise price | 2022-07-01 | |
| 2022-06-30 | Orlinger Klaus Officer (Chief Scientific Officer) | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +48,350 48,350 owned after | $1.66 exercise price | 2022-07-01 | |
| 2022-06-30 | O'Neill Julie Director | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +20,000 20,000 owned after | $1.63 exercise price | 2022-07-01 | |
| 2022-06-30 | Necina Roman Officer (Chief Technology Officer) | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +48,350 48,350 owned after | $1.66 exercise price | 2022-07-01 | |
| 2022-06-30 | Matushansky Igor Officer (Chief Medical Officer) | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +92,950 92,950 owned after | $1.66 exercise price | 2022-07-01 | |
| 2022-06-30 | Kelly Michael Aaron Director | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +20,000 20,000 owned after | $1.63 exercise price | 2022-07-01 | |
| 2022-06-30 | Kaufman David Ross Director | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +20,000 20,000 owned after | $1.63 exercise price | 2022-07-01 | |
| 2022-06-30 | Kandera Reinhard Director, Officer (Chief Financial Officer) | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +92,950 92,950 owned after | $1.66 exercise price | 2022-07-01 | |
| 2022-06-30 | Baker Christine D. Officer (Chief Operating Officer) | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +100,000 100,000 owned after | $1.66 exercise price | 2022-07-01 | |
| 2022-06-30 | Aldag Jorn Director, Officer (Chief Executive Officer) | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +275,250 275,250 owned after | $1.66 exercise price | 2022-07-01 | |
| 2022-04-19 | Orlinger Klaus Officer (Chief Scientific Officer) | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +48,350 48,350 owned after | $1.66 exercise price | 2022-04-20 | |
| 2022-04-19 | Necina Roman Officer (Chief Technology Officer) | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +48,350 48,350 owned after | $1.66 exercise price | 2022-04-20 | |
| 2022-04-19 | Matushansky Igor Officer (Chief Medical Officer) | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +92,950 92,950 owned after | $1.66 exercise price | 2022-04-20 | |
| 2022-04-19 | Kandera Reinhard Director, Officer (Chief Financial Officer) | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +92,950 92,950 owned after | $1.66 exercise price | 2022-04-20 | |
| 2022-04-19 | Baker Christine D. Officer (Chief Business Officer) | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +100,000 100,000 owned after | $1.66 exercise price | 2022-04-20 | |
| 2022-04-19 | Aldag Jorn Director, Officer (Chief Executive Officer) | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +275,250 275,250 owned after | $1.66 exercise price | 2022-04-20 | |
| 2022-02-01 | Orlinger Klaus Officer (Executive VP, Research) | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +12,654 12,654 owned after | $3.00 | 2022-02-01 | |
| 2022-02-01 | Baker Christine D. Officer (Chief Business Officer) | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +22,763 22,763 owned after | $3.00 | 2022-02-01 | |
| 2022-02-01 | Necina Roman Officer (Chief Technology Officer) | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +21,486 21,486 owned after | $3.00 | 2022-02-01 | |
| 2022-02-01 | Matushansky Igor Officer (Chief Medical Officer) | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +24,888 24,888 owned after | $3.00 | 2022-02-01 | |
| 2022-02-01 | Kandera Reinhard Director, Officer (Chief Financial Officer) | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +23,427 23,427 owned after | $3.00 | 2022-02-01 | |
| 2022-02-01 | Aldag Jorn Director, Officer (Chief Executive Officer) | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +39,853 39,853 owned after | $3.00 | 2022-02-01 |